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Abstract
Generally, adenocarcinomas with micropapillary pattern, featuring small papillary tufts lacking a central fibrovascular
core, are thought to have poor prognosis. This pattern has been described in various organs. However, tumor cells
with micropapillary pattern of lung adenocarcinoma are more often seen to float within alveolar spaces
(aerogenous micropapillary pattern, AMP) than in fibrotic stroma like other organs (stromal micropapillary pattern,
SMP) and SMP predominant lung adenocarcinoma (SMPPLA) has not been well described yet. We presented two
cases of SMPPLA which were found in the last four years. Both the cases showed more than 50% of SMP in the
tumor area. The majority of the stromal micropapillary clusters expressed MUC1 and epithelial membrane antigen
along the outer surface of cell membrane. On the other hand, connective tissues surrounding stromal
micropapillary clusters showed no reactivity for epithelial markers (thyroid transcription factor-1 and cytokeratin) or
endothelial marker (D2-40 and CD34). It means clusters of SMP do not exist within air space or lymphatic or vessel
lumens. The tumors with SMP often presented lymphatic permeation and vessel invasion, and intriguingly, one of
the two cases showed metastasis to the mediastinal lymph node. Additionally, both the cases showed EGFR point
mutations of exon 21. These results suggest that SMPPLA might be associated with poor prognosis and effective
for EGFR tyrosine kinase inhibitors.
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Background
A new lung adenocarcinoma classification has been pro-
posed by the International Association for the Study of
Lung Cancer, American Thoracic Society and European
Respiratory Society (IASLC/ATS/ERS). In this classifica-
tion, the micropapillary subtype of lung adenocarcinoma
(MSLA) was recommended as a newly added subtype of
lung adenocarcinoma to lepidic, acinar, papillary, and solid
subtypes defined in the 2004 World Health Organization
(WHO) classification [1,2]. Generally, the micropapillary
pattern is defined as tumor cells growing in papillary tufts,
which lack fibrovascular cores surrounded by lacunar
spaces and has been reported to be associated with a high
incidence of nodal metastasis and poor prognosis [3-6].
This pattern has been described in various organs such as
breast [7,8], urinary bladder [9,10], ovary [11,12], salivary
gland [13], and is known to behave aggressively. In other
organs than the lung, this pattern was observed mainly in
stroma as invasive components (stromal micropapillary
pattern: SMP) [7-19]; however in lung, MSLA is widely
recognized as floating tumor cells within alveolar spaces
(aerogenous micropapillary pattern: AMP) [3,4].
We examined whether SMP predominant subtypes
were present in lung adenocarcinoma. During the period
from February 2007 to December 2010, 559 patients
with lung adenocarcinoma were consecutively treated by
surgical resection at the Kanagawa Cancer Center,
Kanagawa, Japan, and we found only two cases of SMP
predominant lung adenocarcinoma (SMPPLA) (0.36%).
We reported the cases of SMPPLA and attempted to
describe the clinicopathological features.
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A 49-year-old Japanese man was referred to the hospital
with lung adenocarcinoma, which was diagnosed by the
transthoracic needle biopsy. A computed tomography
(CT) scan detected a 32 mm-sized localized solid tumor
in the right upper lobe and swelling of the mediastinal
lymph node (Figure 1a). He was an ex-smoker and
admission laboratory tests showed increased carcinoem-
bryonic antigen (9.6 ng/mL). A right upper lobectomy
with lymph node dissection was performed and the
tumor was diagnosed as lung adenocarcinoma in patho-
logical T2aN2M0 and stage IIIA determined on the
basis of the TNM classification of Union of Interna-
tional Cancer Control [20]. After that, he underwent
postoperative adjuvant chemotherapy, and he was alive
without recurrence ten months after operation.
Case2
A 57-year-old Japanese man who was a never smoker was
referred to the hospital with abnormal shadow on his
chest CT scan. A CT scan detected a 29 mm-sized loca-
lized solid nodule with pleural indentation in the right
upper lobe, and the histological diagnosis of the tumor
by transbronchoscopic biopsy was lung adenocarcinoma
(Figure 1b). Laboratory tests showed slightly elevated
squamous cell carcinoma antigen (1.6 ng/mL). A right
upper lobectomy with lymph node dissection was per-
formed and diagnosed lung adenocarcinoma in patholo-
gical T2aN0M0 and stage IB. After that, he underwent
postoperative adjuvant chemotherapy, and he was alive
without recurrence nine months after operation.
Pathological findings
The excised specimens were fixed in a solution of 10%
buffered formaldehyde and the sections were embedded
in paraffin. Four micrometer-thick sections including the
largest cut surface of the tumor were prepared and
stained with hematoxylin and eosin (HE), alcian blue and
elastica-van-Gieson (AB-EVG) stain. Immunohistochem-
ical staining was performed with the primary antibodies
listed in Table 1. Lepidic, acinar, papillary and solid sub-
types of lung adenocarcinoma were determined accord-
ing to the 2004 WHO classification. AMP of lung
adenocarcinoma was determined according to the
IASLC/ATS/ERS international multidisciplinary classifi-
cation of lung adenocarcinoma [1].
Macroscopic examination of the excised specimens
showed the sharply-demarcated tumor measuring 36 ×
25 × 30 mm in size, white in color on cut surface in the
case 1 (Figure 2a), and the tumor measuring 33 × 20 ×
40 mm in size, grayish white in color on cut surface in
the case 2 (Figure 2b).
Microscopically, the tumors of both the cases were
composed of stromal micropapillary predominant adeno-
carcinoma, which were proliferation of nonmucinous aty-
pical cuboidal epithelial cells. In the case 1, the tumor
was composed of 55% SMP, 5% lepidic, 30% acinar, 5%
papillary pattern and 5% AMP (Figure 3a). In the case 2,
the tumor was composed of 55% SMP, 20% lepidic and
25% acinar pattern (Figure 3b) and lacked AMP. In both
the cases, lymphatic and vessel invasion were often
observed. Lymphatic invasion was confirmed on immu-
nohistochemistry using D2-40 antibody. The case 1
showed pleural invasion and resected regional lymph
nodes had metastatic foci composed of tumor cells with a
micropapillary pattern (Figure 4).
Immunohistochemically, the outer surface of the SMP
cell clusters in both the cases showed membranous
expression of MUC1 and epithelial membrane antigen
(EMA), indicating an ‘inside-out’ pattern. Both the cases
showed E-cadherin expression on intercellular cell mem-
branes of micropapillary tufts of SMP tumor cells.
Tumor cells constituting SMP showed positive staining
for Ki-67 (MIB-1, Dako, Glostrup, Denmark); positive
Figure 1 Enhanced chest CT of the lung. Chest CT of case 1 (a)
and case 2 (b) showed a tumor of the right upper lobe of the lung.
(a) Chest CT revealed a tumor with pleural indentation, without
ground glass opacity (GGO). The tumor was 32 mm in diameter and
mildly enhanced. (b) Chest CT revealed a nodule with GGO, pleural
indentation, air bronchogram and venous involvement. The nodule
was 29 mm in diameter and mildly enhanced.
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rate were 24% in case 1, 62% in case 2. In SMP compo-
nent, positive and negative tumor cells for thyroid tran-
scription factor-1 (TTF-1) and surfactant protein A (SP-
A) staining were observed in the case 1, on the other
hand, the case 2 showed TTF-1 expression and SP-A
repression in almost all tumor cells. Tumor cells outside
SMP showed MUC1 and EMA expression on free surface
of cell membrane, but MUC1 positive cells were fewer
than those in SMP. Tumor cells outside SMP in case 1
showed strong TTF-1 expression. D2-40, CD34 and fac-
tor VIII were not found in cells constituting micropapil-
lary tufts. Moreover TTF-1, cytokeratin (CK), D2-40,
CD34 and factor VIII were negative in luminal inner sur-
face surrounding micropapillary tufts (Table 1 Figure 5a-
d). These results means micropapillary tufts of SMP lack
fibrovascular core and were not located within alveolar
space, vascular or lymphatic vessels.
Mutational analysis
A study of epidermal growth factor receptor (EGFR)
gene status of exon 19 and 21 was performed by the
methods described elsewhere [21]. Written informed
consent for genetic analysis of the tumor cells was
obtained from the patients. As a result, both the cases
showed an L858R point mutation at exon 21.
Discussion
In the two cases presented, we recognized that tumor
cells of SMP had reduced expression of SP-A, but tumor
cells outside SMP had its strong expression. Additionally,
we identified the tumor cluster cells were surrounded by
the connective tissue which was negative for TTF-1 or
CK. And these components were also negative for D2-40
and CD34. The results suggested micropapillary tufts of
SMP were not located within alveolar space, vascular or
lymphatic vessels but in stroma and reduced the pheno-
typic expression like SP-A [22].
AMP of MSLA has been reported to express of MUC1
[6]. We identified expression of MUC1 and EMA in the
outer surface of papillary clusters like those in AMP of
the case 1. This staining pattern is called as an ‘inside-
out’ pattern in the invasive micropapillary carcinoma of
Table 1 Antibodies used and immunohistchemical result
Antibody Clone Dilution Source Stroma around the micropapillary clusters Tumor cells
in SMP outside SMP
Case1 Case2 Case1 Case2 Case1 Case2
MUC1 Ma695 1:100 Novocastra 0 0 2+ 2+ 1+ 2+
EMA E29 Pre-diluted Cell Marque 0 0 2+ 2+ 2+ 2+
E-cadherin NCH38D 1:100 DakoCytomation 0 0 2+ 2+ 2+ 2+
CK AE1/AE3 Pre-diluted Nichirei 0 0 2+ 2+ 2+ 2+
TTF-1 8G7G3/1 1:100 DakoCytomation 0 0 1+ 2+ 2+ 2+
SP-A PE10 1:100 Dako 0 0 1+ 0 2+ 2+
D2-40 D2-40 Pre-diluted Nichirei 0 0 0 0 0 0
CD34 Nu-4A1 Pre-diluted Nichirei 0 0 0 0 0 0
FactorVIII polyclonal 1:200 DAKO 0 0 0 0 0 0
EMA, epithelial membrane antigen; CK, cytokeratin; TTF-1, thyroid transcription factor-1; SP-A, surfactant protein A.
Novocastra, Newcastle Upon Tyne, UK; Cell Marque, Hot springs, AR, USA; DakoCytomation, Carpinteria, CA, USA; Dako, Kyoto, Japan; Nichirei, Tokyo, Japan;
DAKO, Glostrup, Denmark.
0, no positive cells; 1+, positive tumor cells less than 10%; 2+, 10% or more.
Figure 2 Macroscopic findings. Macroscopic examination of
excised specimens showed the tumor measuring 36 × 25 × 30 mm
in size, white in color on cut surface in the case 1 (a), and the
tumor measuring 33 × 20 × 40 mm in size, grayish-white in color
on cut surface containing areas of hemorrhage in the case 2 (b).
White squares in Figure 2a and 2b correspond to photomicrographs
of Figure 3a and 3b, respectively.
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breast [7,8] and several organs [9-19]. Therefore, the
polarity called as an ‘inside-out’ pattern of the tumor
cells is thought to be a characteristic feature in SMP
and AMP of lung adenocarcinoma.
Previous studies have reported that a micropapillary
pattern is associated with a poor prognosis in stage I
lung adenocarcinoma because of its aggressive behavior,
as shown by frequent lymph node metastasis, lymphatic
permeation, vascular invasion and pleural invasion [4-6].
In the current two cases, lymphatic permeation and vas-
cular invasion were often observed. In addition, the case
1 showed pleural invasion and the resected regional
Figure 3 Photomicrographs. Stromal micropapillary pattern characterized by papillary structures with tufts lacking a central fibrovascular core
and surrounding clear spaces in fibrotic stroma was seen in both case 1 (a) and case 2 (b). (HE stains ×100; inset, ×400)
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Figure 4 Photomicrographs. (a) A resected regional lymph node had metastatic foci composed of tumor cells with a micropapillary pattern in
the case 1. (HE stain, ×200) (b) Vessel invasion by tumor cells in the case 1. (AB-EVG stain, ×100) (c, d) Tumor cells in lymphatic ducts, which
were covered by D2-40 positive endothelial cells. (c, ×200, case 1; d, ×400, case 2).
Figure 5 Immunohistochemical photomicrographs of case 1. (a) Tumor clusters of stromal micropapillary pattern had MUC1 expression on
the outer surface strongly, indicating ‘inside-out’ pattern. (×200) (b) D2-40 and (c) CD34 were not found in cells consisting micropapillary tufts
and (d) CK was not found in connective tissue surrounding the tumor cells. (b, c, ×200; d, ×400).
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lymph node had metastatic foci composed of tumor
cells with a micropapillary pattern. Though it is too
early to refer to prognosis of SMPPLA because of short
duration of observation, we may say SMPPLA has
strong association with vascular invasion.
We also performed a mutational analysis of EGFR
gene mutations and both the cases showed EGFR muta-
tions of exon 21. These results suggest that SMPPLA
might be associated with poor prognosis and effective
for EGFR tyrosine kinase inhibitors.
In conclusion, we recognized the presence of
SMPPLA. Since SMPPLA is very rare as far as we inves-
tigated, further studies are required to determine the
clinical significance of SMPPLA in detail.
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